Cheryl Guttman Krader, BS, Pharm

Personally tailored intervention generates patient interest, QoL improvements.

Benefit evident regardless of metastasis site, phase III analysis shows.

~40% of sipuleucel-T recipients in lowest PSA quartile alive after 5 years.

Although active surveillance for prostate cancer is on the rise in younger, privately insured men, many patients do not undergo a repeat biopsy.

The combination appears to be a more powerful predictor than mpMRI/PSA density.

Retrospective analyses of data collected in a real-world study provide assurance about using nivolumab (Opdivo) to treat elderly patients with metastatic renal cell carcinoma who have failed previous therapy.

“We believe that our study underscores the importance of improving dissemination of the guidelines and their implementation and uptake in practice,” says researcher Nikhil Waingankar, MD, MSHP.

Apalutamide (Erleada) treatment in men with nonmetastatic castrate-resistant prostate cancer significantly improves metastasis-free survival and does so without adversely affecting health-related quality of life.

“A multivariable analysis confirmed that AR-V7 status independently predicted PSA response,” says researcher Matthias Heck, MD.

Findings from a retrospective analysis of data collected at the National Institutes of Health provide insight on how multiparametric MRI/transrectal ultrasound-fusion biopsy (“fusion biopsy”) may be affecting management patterns and outcomes for men with prostate cancer.

Analyses with patients stratified into three groups by age showed that an emulsified microdose desmopressin acetate nasal spray (Noctiva) consistently extended the first uninterrupted sleep period in a clinically meaningful manner for patients of all ages.

While a recent study of salvage radical prostatectomy after focal therapy demonstrates satisfactory functional outcomes, oncologic outcomes were not as good as after primary RP, said researcher Jaime O. Herrera-Caceres, MD.

An analysis of trends in the management of renal masses shows growing use of active surveillance, although some data suggest “a proportion of surveillance cases may have been due to lack of access to care instead of truly choosing active surveillance,” says study author Ketan K. Badani, MD.

A private urology practice can successfully transform itself from a fee-for-service payment model for cancer care to an episode-based system, although it remains to be determined whether operating under this model also translates into cost savings.

“Patients should be informed of the less-than-ideal stone-free rates and secondary morbidity when residual fragments are present after this treatment modality,” says researcher Igor Sorokin, MD.

The analysis “gives urologists the first accurate idea of how many physician assistants and nurse practitioners are working in urology,” says researcher Raymond Fang.

New study findings provide evidence to guide management decisions for patients with prostate cancer who have lymph node metastases following radical prostatectomy.

Findings from a cost-effectiveness analysis provide useful information for physicians, patients, and payers about available treatments for lower urinary tract symptoms due to BPH, according to the authors who conducted it.

Urology Times’ “Best of AUA 2015” report provides a guide to the meeting’s take-home messages in 15 therapeutic areas-an information-packed, condensed summary of the top papers and presentations.

A novel optical imaging technology is showing promise as a potential diagnostic tool for renal cell carcinoma.

The rate of prostate biopsy declined steadily and significantly over a contemporary 10-year period, results of a retrospective longitudinal review of data from the Veterans Health Administration show.

Ureteroscopy is being increasingly used for surgical management of nephrolithiasis in pediatric patients, and that trend appears to be associated with cost benefits, a recent study indicates.

Flexible ureteroscopy is a safe and highly effective approach for treating proximal ureteral stones measuring

Adding an anticholinergic medication to an alpha-blocker does not appear to improve ureteral stent-related discomfort compared to monotherapy with an alpha-blocker alone, according to research presented by investigators from the University of Wisconsin, Madison.

Repeated onabotulinumtoxinA 100 U (onabotA [Botox]) injections continue to provide benefit for patients with overactive bladder syndrome and urinary incontinence and without evidence of any new safety concerns, according to results of a pre-specified interim analysis in an open-label, 3-year extension study.

Propulsion with low-intensity ultrasound is showing promise as a safe and effective method for noninvasive repositioning of kidney stones, according to the findings of a first human feasibility study being conducted by researchers at the University of Washington, Seattle.

A review of initial surgical management for patients with urolithiasis has identified an association between urologist self-referral and an increased likelihood of undergoing computed tomography imaging and extracorporeal shock wave lithotripsy (ESWL) compared with non-self-referring physicians.

A retrospective evaluation to determine adherence to the AUA clinical practice guideline for the management of lower urinary tract symptoms/BPH among urologists practicing in an academic setting found generally positive results, but with room for improvement, researchers reported at the AUA annual meeting in Orlando, FL.

Sexual function in men with lower urinary tract symptoms/BPH generally declines over time whether or not they are treated with medication. However, the magnitude of worsening differs depending on the treatment received, according to findings from the Medical Therapy of Prostatic Symptoms study.

Data from 2 years of prospective follow-up in a multinational study show that the prostatic urethral lift (PUL [UroLift System, Neotract, Inc., Pleasanton, CA]) is a safe procedure that provides durable, clinically meaningful improvement of lower urinary tract symptoms due to BPH, reported Claus G. Roehrborn, MD, at the AUA annual meeting in Orlando, FL.